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An inhibitor of serine proteases, neuroserpin, acts as a
neuroprotective agent in a mouse model of neurodegenerative
disease
Abstract
Various studies suggest that proteolytic activity may be involved in a number of neurodegenerative
disorders, including stroke and seizure. In this report, we examined the role of tryptic serine proteases,
plasminogen activators (PAs), in the evolution of a neurodegenerative disease. Transgenic mice
overexpressing an axonally secreted inhibitor of serine proteases (neuroserpin) were crossed with mice
characterized by a "dying-back" motor neuron disease [progressive motor neuronopathy (pmn/pmn)].
Compared with pmn/pmn mice that showed an increase in PA activity, double mutant mice had
decreased PA activity in sciatic nerves and spinal cord; their lifespan was increased by 50%, their motor
behavior was stabilized, and histological analysis revealed increased numbers of myelinated axons and
rescue of motoneuron number and size. This is the first report showing that a class of serine proteases
(PAs) may be involved in the pathogenesis of a motor neuron disease and more specifically in axonal
degeneration. Inhibiting serine proteases could offer a new strategy for delaying these disorders.
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Various studies suggest that proteolytic activity may be involved in a number of neurodegenerative disorders, including stroke and
seizure. In this report, we examined the role of tryptic serine proteases, plasminogen activators (PAs), in the evolution of a neurodegen-
erative disease. Transgenicmice overexpressing an axonally secreted inhibitor of serine proteases (neuroserpin) were crossedwithmice
characterized by a “dying-back” motor neuron disease [progressive motor neuronopathy (pmn/pmn)]. Compared with pmn/pmnmice
that showed an increase in PA activity, doublemutantmice had decreased PA activity in sciatic nerves and spinal cord; their lifespanwas
increased by 50%, their motor behavior was stabilized, and histological analysis revealed increased numbers of myelinated axons and
rescue of motoneuron number and size. This is the first report showing that a class of serine proteases (PAs) may be involved in the
pathogenesis of a motor neuron disease and more specifically in axonal degeneration. Inhibiting serine proteases could offer a new
strategy for delaying these disorders.
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Introduction
Proteolytic activity has been suggested to be involved in a number
of neurological disorders, including stroke, seizure, and Walle-
rian degeneration. Recently, it has been shown that plasminogen
activators (PAs) are implicated in axonal degeneration in a
mousemodel of multiple sclerosis, experimental allergic enceph-
alomyelitis (Lu et al., 2002; East et al., 2005), and other studies
have shown that PAs are activated duringWallerian degeneration
(Bignami et al., 1982; Siconolfi and Seeds, 2001)
PAs [tissue PA (tPA) and urokinase PA (uPA)] catalyze the
conversion of serum plasminogen to plasmin, the active fibrino-
lytic enzyme, and they are expressed in the CNS in neurons and
glia. PAs have been shown to play a role in axonal elongation and
nerve regeneration (Siconolfi and Seeds, 2001). It has been pro-
posed that deregulation of the PA system could aggravate neuro-
degenerative processes in many pathological situations. For ex-
ample, PAs and in particular tPAmediate neuronal degeneration
in models of stroke, epilepsy, and in Alzheimer’s disease (for
review, see Melchor and Strickland, 2005).
In this report, we determined whether PAs could be involved
in the neurodegenerative process of axons and cell bodies of mo-
toneurons in a mouse model of a neurodegenerative disease
called pmn, for progressive motoneuropathy. pmn/pmnmice are
characterized by a “dying-back” motor neuronopathy (Schmal-
bruch et al., 1991); the pathophysiology begins in the axon ter-
minals by an unknown process, followed by a degeneration of the
motoneuron cell bodies. We first show that the activity of PA is
increased in sciatic nerves and spinal cord of pmn/pmn mice
compared with controls. We then crossed pmn mice with trans-
genicmice that overexpress an inhibitor of PAs, i.e., neuroserpin.
In these double mutant mice, the lifespan, the motor behavior,
the number of surviving motoneurons in the spinal cord and




pmn mice were obtained from the laboratory of J. L. Gue´net (Institut
Pasteur, Paris, France). Mice that overexpressed neuroserpin [TgN
(hsNSwt)682 line called ThyNs mice] (Cinelli et al., 2001) were crossed
with pmn/ to generate pmn/;ThyNs progeny (F1); these mice were
crossed to generate the F2 line that contained pmn/pmn;ThyNs mice.
Mice genotypes were screened by PCR. All of the experimental proce-
dures were approved by the Ethical Committee for Animal Experimen-
tation of the Geneva Veterinary Office.
Behavioral analysis
Spontaneous locomotor activity was recorded in a photocell activity
chamber (Leticamodel LE 8811; Bioseb, Chaville, France), and data were
analyzed using the program SeDaCom32 (Bioseb).
Analysis of myelinated axons in the facial and phrenic nerves
Nerves were removed, postfixed, dehydrated, sectioned, and stainedwith
Boracs blue as described previously (Ferri et al., 2003).
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Histological analysis of fluorescently labeled sciatic motoneurons
Labeling was performed as described previously (Perrelet et al., 2004).
The fluorescent retrograde tracer fluorogold (Fluorochrome, Engle-
wood, NJ) was injected into the gastrocnemiusmuscle, and animals were
killed 1 week later (at 40 d of age). The spinal cords were sectioned at 30
m on a cryostat. Labeled motoneurons were counted in the ventral
horn of the spinal cord in segments L3–L6.
Counting of motoneurons
In spinal cord. Mice were perfused at 12, 20, and 40 d of age. The spinal
cords were cryoprotected in 20% sucrose, sectioned at 14 m on a cryo-
stat, and stained with cresyl violet.
In cranial nuclei.After perfusion the brains were removed, dehydrated
in alcohol, embedded in paraffin, sectioned at 8mon amicrotome, and
stained with cresyl violet.
In both cases, only motoneurons with a clearly identifiable nucleus
were counted on both sides of the spinal cord in every fifth section; the
values were multiplied by five to give the final estimate of the number of
motoneurons.
Analysis of the cell body surface of motoneurons
The cross-sectional area of the motoneurons was measured with Ro-
boSoftware (Palm Microlaser Technologies, Bernried, Germany).
Zymographic assay for PAs
Mice were killed and perfused with PBS/
liquemine. Sciatic nerves were removed,
crushed with a Polytron, and centrifuged to
eliminate remaining cell fragments. Zymo-
graphic assays were done (with 10 g of pro-
tein) according to Vassalli et al. (1984). The op-
tical density of the bands was measured by
scanning the gels and determining the number
of pixels per surface area (NIH ImageJ version
1.30; Wayne Rasband, National Institutes of
Health, Bethesda, MD).
Western blotting
Western blotting was performed as described
previously (Perrelet et al., 2004). Primary anti-
bodies included anti-3-tubulin (mouse,
1:500; Chemicon, Hofheim, Germany) and
anti-actin (goat, 1:2000; Santa Cruz Biotech-
nology, Santa Cruz, CA). Secondary antibodies
included anti-mouse and anti-goat IgG, horse-
radish peroxidase linked. The optical density of
the bandswasmeasured as described previously
for zymography.
Results
PAs are activated in sciatic nerves and
spinal cord of pmn/pmnmice
The initial goal of our work was to deter-
mine whether PAs can play a role in the
pathophysiology of the pmn dying-back
motor neuronopathy. These mice develop
muscle weakness and atrophy starting at 2
weeks of age and die at 6 weeks of age.
We first observed that PAs were differen-
tially expressed in sciatic nerves of control
andmutant mice (Fig. 1A–C). A quantita-
tive analysis by densitometry at 12, 20, and
40 d of age (Fig. 1B,C) showed no differ-
ence in PA activity in pmn/pmn mice and
control mice at a presymptomatic stage
(12 d of age), whereas it was already in-
creased in pmn/pmnmice at 20 d of age. PA
activity increased even further at 40 d of
age, corresponding to the end stage of the
disease.
Differential expression of PA activity was also observed in the
spinal cord; gel zymography showed that both tPA and uPA ac-
tivitywere higher in the spinal cord of 20- and 40-d-old pmn/pmn
mice versus control mice (Fig. 1D–F). These results suggest that
PAs may be candidate factors for playing a role in axonal degen-
eration and motoneuron loss in pmn/pmn mice. To determine
which cell types overexpress PAs in the spinal cord and sciatic
nerves, we performed in situ hybridization for both tPA and uPA
mRNAs on sections from control and pmn/pmn mice. In spinal
cords, an increase in tPAmRNAwas observed in pmn/pmn com-
paredwith controlmice in various cell types (such as neurons and
glia) and not only inmotoneurons (data not shown). uPAmRNA
was undetectable, probably because of the low expression of this
serine protease in the spinal cord (Fig. 1D).We did not detect any
labeling of uPA and tPA mRNA in sciatic nerves, suggesting that
the primary site of PA synthesis was in the spinal cord (data not
shown). To study whether immune cells may be involved in ax-
onal degeneration or PA expression, we compared extracts of
sciatic nerves and spinal cord from pmn/pmn and controlmice by
Figure 1. A, Gel zymography of PA activity in sciatic nerves of control and pmn/pmnmice at 40 d of age.B, C, Quantification of
tPA (B) and uPA (C) activities at 12, 20, and 40 d of age. D, Gel zymography of PA activity in spinal cord of control and pmn/pmn
mice at 40 d of age. E, F, Quantification of tPA (E) and uPA (F ) activities; values were normalized to the level of controls that were
takenas 100%(n3; ANOVAanalysis, *p0.01, **p0.001). std, Standard. PAactivity in sciatic nerves and in spinal cordwas
similar between pmn/pmnmice and control mice at a presymptomatic stage (12 d), whereas there was an increase in both uPA
and tPA in pmn/pmnmice at a symptomatic age (20 and 40 d).
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immunoblotting using an antibody (CD11) that is specific to
macrophages and microglia. We found no difference in the ex-
pression of this antigen, strongly suggesting that there is no im-
mune response to axonal degeneration in pmn/pmn mice (data
not shown).
Neuroserpin overexpression partially rescued the phenotype
of pmn/pmnmice
To determine whether inhibiting PAs may modify the neurode-
generative process in the pmn phenotype, we crossed pmn/pmn
mice withThyNs transgenicmice that overexpress an inhibitor of
PAs, neuroserpin, under the control of a neuronal promoter
(Thy1.2) (Cinelli et al., 2001). It has been shown previously that
neuroserpin can inhibit both tPA and uPA in vivo (Yepes et al.,
2000) and that it is neuronally expressed and axonally secreted
(Osterwalder et al., 1998). Because PAs are also secreted proteins
that function in the extracellular matrix, neuroserpin provides a
tool for interfering with PA activity under pathological condi-
tions. Because the neuroserpin and pmnmutantmice weremain-
tained in different strains (C57BL/6 and SV129, respectively), we
also analyzed offspring of ( pmn/  C57BL/6)  ( pmn/ 
C57BL/6) matings and showed that disease progression in pmn/
pmn mice was not significantly affected by the genetic back-
ground (data not shown). No gene dosage effect was observed
when comparing pmn/pmn mice carrying one or two copies of
the neuroserpin transgene. By zymographic analysis, we con-
firmed that exogenous neuroserpin overexpression reduced PA
activity in sciatic nerve extracts of pmn/pmn;ThyNs mice com-
pared with pmn/pmnmice (Fig. 2A).
Hindlimb atrophy and muscle weakness were evident at 2
weeks of age in pmn/pmnmice, and all mice died at40 d of age
(41.7  3.8; n  6). In contrast, when pmn mice were crossed
with transgenic mice overexpressing neuroserpin, the lifespan of
the pmn/pmn offspring carrying the ThyNs transgene was pro-
longed to 60 d of age (61.3  5.9; n  5), i.e., an increase of
50% ( p 0.001) (Fig. 2B). We did not observe a difference in
the lifespan of control and ThyNsmice.
Neuroserpin overexpression did not provide a protection
against the massive weight loss seen in pmn/pmn mice. The
weight of the pmn/pmn;ThyNs mice stabilized to a value only
slightly higher than homozygote pmn/pmn before death (Fig.
2C). A photocell activity chamber was used to monitor sponta-
neous activity (Fig. 2D). In both pmn/pmn and pmn/pmn;ThyNs
mice, the activity level was dramatically lower than in controls.
However, in pmn/pmn;ThyNs mice, spontaneous activity de-
creased more slowly and gradually compared with pmn/pmn
mice.
In previous studies, we have shown that certain factors such as
ciliary neurotrophic factor act to protect both the axon and the
cell body and thus increase the lifespan of pmnmice (Sagot et al.,
1995a). In contrast, other molecules such as bcl-2 and glial cell
line-derived neurotrophic factor were only capable of rescuing
the motoneuron cell bodies without preserving the axons; under
these conditions, the lifespan of the pmn mice was unaltered
(Sagot et al., 1995b, 1996). In the present experiments, we hy-
pothesized that an increase in PA levels may play a role in mo-
toneuron degeneration, and thus inhibition of PAs by neuroser-
pin should protect motor axons, motoneuron cell bodies, or
both.Myelinated axons were counted in the facial motor nerve of
12-, 20-, and 40-d-old pmn/pmn, pmn/pmn;ThyNs, and control
littermates. At a presymptomatic age, there was no difference in
the number ofmyelinated axons between the different groups. As
expected, the number of facial axons in pmn/pmn mice was
strongly reduced at symptomatic ages (Fig. 3A,B,G). In contrast,
axon loss was reduced in pmn/pmn;ThyNs compared with pmn/
pmnmice (Fig. 3B,C,G).
Myelinated fibers in the phrenic nerve that innervate the dia-
phragm have been reported to be severely affected in pmn/pmn
mice, suggesting that these mice die by respiratory failure
(Schmalbruch et al., 1991). To determine whether neuroserpin
overexpression prevented this loss, myelinated axons were
counted in the phrenicmotor nerve at the end stage of disease (40
d of age) in pmn/pmn, pmn/pmn;ThyNs, and control littermates.
As described previously (Sagot et al., 1995b; Ferri et al., 2003), the
number of phrenic axons was decreased by 45% in pmn/pmn
mice; this loss was partially prevented in neuroserpin overex-
pressing pmn/pmnmice (Fig. 3I).
The pmn disease results from a mutation in the tubulin chap-
erone E (tbce) gene that leads to a decreased number of microtu-
bules in the axons (Martin et al., 2002). To determine whether
neuroserpin overexpression could stabilize microtubules, we ex-
amined the level of 3-tubulin as a quantitative index of micro-
tubule abundance. In the sciatic nerve, at 40 d of age and as
determined by Western blotting, the level of 3-tubulin was de-
creased by 76% in pmn/pmn mice compared with controls (Fig.
3H), whereas in the presence of neuroserpin overexpression, it
was decreased by only 55%. Thus, neuroserpinmay contribute to
stabilizing or restoring the polymerization of microtubules.
Because pmn/pmn mice are characterized by a loss of mo-
toneurons, we examined whether overexpression of neuroserpin
could prevent neuronal degeneration. Motoneurons in the lum-
bar spinal cord and in four cranial nuclei (oculo/trochlear, tri-
geminal, facial, and hypoglossal) were counted. Gastrocnemius
motoneurons in the spinal cord were selectively labeled by retro-
grade transport after injection of fluorogold into the gastrocne-
Figure 2. A, PA activity is strongly reduced in pmn/pmn;ThyNsmice. Gel zymography of PA
activity in sciatic nerves of control, pmn/pmn, and pmn/pmn;ThyNs mice at 40 d of age. B–D,
Neuroserpin overexpression extends lifespan and stabilizes motor function in pmn/pmnmice.
B, Survival of pmn/pmn (n 6) and pmn/pmn;ThyNs (n 5) mice. The mean survival of
pmn/pmn;ThyNsmice (bold line) is significantly increased compared with pmn/pmnmice (thin
line) ( p 0.001). C, Weight of control (n 6), pmn/pmn (n 6), and pmn/pmn;ThyNs (n
6) mice. D, Motor activity of control (n 6), pmn/pmn (n 6), and pmn/pmn;ThyNs (n 6)
mice (ANOVA analysis, *p 0.01).
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mius muscle (Fig. 3D–F,J), and the total
number of lumbar spinal cord motoneu-
rons were determined after cresyl violet
staining (Fig. 3K). Whereas spinal mo-
toneurons degenerated in pmn/pmnmice,
neuroserpin overexpression partially pre-
vented the decrease in neuron number
(50% reduction in neuronal loss com-
pared with pmn/pmn mice at 40 d of age)
(Fig. 3E,F, J,K). Similarly, whereas four
populations of motoneurons in cranial
nuclei were decreased in pmn/pmn mice,
neuroserpin overexpression partially pre-
vented the decrease in the number of both
oculo/trochlear and facial nuclei mo-
toneurons (Fig. 4A) and in the size of facial
motoneurons (Fig. 4B–E).
Discussion
In this study, we examined the role of PAs,
a class of serine proteases, in axonal degen-
eration and motoneuron loss in the pmn
mouse. The mutation in pmn mouse has
been localized recently to a tubulin chap-
erone E gene (tbce) (Bommel et al., 2002;
Martin et al., 2002). A mutation of human
tbce is responsible for hypoparathyroidism–
retardation–dysmorphism syndrome that
comprises neurological symptoms (Parvari
et al., 2002). Interestingly, a recent study
shows that human giant axonal neuropa-
thy, an autosomal recessive neurodegen-
erative disorder, is related to the degrada-
tion of tubulin folding cofactor B (Wang et
al., 2005). Thus, pmn mice may provide a
useful model for studying diseases related
to tubulin modification and not only to
motoneuron disease.
The goal of our work is to determine
whether PAs can play a role in the pathol-
ogy of the pmnmouse model. We first ob-
serve an increase in PA activity at a symp-
tomatic stage (20 and 40 d of age) in sciatic
nerves and spinal cord of pmn/pmn mice
compared with control mice. No differ-
ence in PA activity is observed at a pre-
symptomatic stage, suggesting that PA ac-
tivation may be acting primarily at a later
stage of the disease.
To understand whether this activation
of PAs is relevant to mechanisms impli-
cated in axonal degeneration and mo-
toneuron loss, we determined whether the
overexpression of an inhibitor of PAs,
neuroserpin, could affect the disease pro-
gression and symptoms in pmn/pmnmice.
Therefore, we crossed pmn/pmnmice with
neuroserpin overexpressing mice (ThyNS
under the control of a neuronal promoter
Thy1.2) and observed an inhibition of PA
activity in sciatic nerves of pmn/pmn;
ThyNs mice by zymographic analysis,
demonstrating that neuroserpin overex-
Figure 3. Neuroserpin overexpression partially protects motor axon and motoneuron loss in pmn/pmn mice. A–C, Cross
sections of facial nerves in control (A), pmn/pmn (B), and pmn/pmn;ThyNs (C)mice at 40 d of age. Insets, Threefoldmagnification.
InB, there are fewermyelinated facial nerves, and they are less compact than inA or C.D–F, Transverse sections of lumbar spinal
cords from control (D), pmn/pmn (E), and pmn/pmn;ThyNs (F ) mice after fluorogold labeling of motoneurons. G, Counts of
myelinated axons in facial nerves at 12, 20, and40dof age. Inpmn/pmn;ThyNsmice (n5), thenumber ofmyelinated axonswas
significantly increased (ANOVA analysis, *p 0.01) compared with pmn/pmn (n 4).H, Western blot for3-tubulin in sciatic
nerves of control, pmn/pmn, and pmn/pmn;ThyNs mice at 40 d of age and quantification (n 3). Values were normalized to
-actin; controlswere taken as 100%(ANOVAanalysis, *p0.01). I, Counts ofmyelinated axons in phrenic nerves at 40dof age.
In pmn/pmn;ThyNs mice (n 3), the number of myelinated axons was significantly increased (ANOVA analysis, *p 0.01)
comparedwithpmn/pmnmice (n3). J, Counts of fluorogold-labeledmotoneurons at 40dof age. Inpmn/pmn;ThyNsmice (n
4), the number of fluorogold-labeled motoneurons was significantly increased (ANOVA analysis, *p 0.01) compared with
pmn/pmnmice (n 4). K, Counts of cresyl violet-labeledmotoneurons in the lumbar spinal cord at 12, 20, and 40 d of age (n
3) (ANOVA analysis, *p 0.01, **p 0.001). Scale bars: A–C, 50m; D–F, 100m.
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pression inhibits PA activity in axons. The
apparition of symptoms in both pmn/pmn
mice and in pmn/pmn;ThyNs mice occurs
at 2 weeks of age, but we observed a 50%
increase in the lifespan of pmn/pmn;ThyNs
compared with pmn/pmn mice. Further-
more, the body weight and the motor ac-
tivity are stabilized at the end stage of dis-
ease. These results suggest that PAs play a
deleterious role at later stages of the disease
and that inhibition by neuroserpin can de-
lay the disease progression and increase
the lifespan of pmn/pmnmice.
Moreover, we show that neuroserpin
overexpression partially protects myelin-
ated motor axons of facial and phrenic
nerves and protects cranial motoneurons
in the oculo/trochlear and facial nuclei as
well as motoneurons in the spinal cord of
pmn/pmnmice. Cranial motoneurons also
exhibit a selective vulnerability in different
mousemodels of amyotrophic lateral scle-
rosis and in human patients; a selective
protection of cranial nuclei has been ob-
served previously in pmn/pmn;Wlds mice
(Ferri et al., 2003). A number of hypothe-
ses have been put forward to explain why
motoneurons do not display a uniformde-
generation, including a differential expres-
sion of glutamate receptors and glutamate
transporter subtypes. Motoneurons in different cranial nuclei
may also exhibit a differential sensitivity to PAs and/or neuroser-
pin or a differential level of expression of these genes.
Several mechanisms have been proposed to explain the role of
PAs in axonal degeneration. PAs may promote demyelination
because plasmin can directly degrade myelin basic proteins
(Cammer et al., 1978). Furthermore, plasmin is the key initiator
of the matrix metalloproteinase (MMP) activation cascade and
has been documented to play an important role in the breakdown
of myelin membranes (for review, see Cuzner and Opdenakker,
1999). Moreover MMP7, MMP9, and MMP12 are activated in
optic nerve axons during Wallerian degeneration (Hughes et al.,
2002). PAs could also play a direct role in apoptosis of motoneu-
rons. Indeed, it has been shown that tPA plays a role in neuronal
apoptosis (Flavin et al., 2000) and that neuroserpin protects neu-
rons from ischemia-induced death (for review, see Galliciotti and
Sonderegger, 2006). One prevailing hypothesis is that proteolytic
disruption of the basement membrane by tPA may be the trigger
that initiates apoptosis. Thus, the capacity of neuroserpin to
block tPA-induced degradation of the basement membrane may
explain the ability of neuroserpin to reduce neuronal death.
Interestingly, in our mouse model, we observed that neuro-
serpin overexpression partially rescues the microtubule loss in
sciatic nerves of pmn/pmn mice. It has been shown previously
that tPA can play a role in microtubule destabilization in hip-
pocampal neurons (Medina et al., 2005). Together, these results
suggest that tPA could play a role in the microtubule loss ob-
served in pmn/pmn mice and that neuroserpin overexpression
may protect pmn/pmn mice by controlling tPA and its effect on
microtubule abundance. Several studies have shown that tPA can
play a protective role in axonal regeneration and functional re-
covery after sciatic nerve injury (Siconolfi and Seeds, 2001; Zou et
al., 2006). These results are not incompatible with our own ob-
servations because, in experimental paradigms using nerve crush,
it is evident that extracellular debris must be removed by some
type of proteolytic system before axonal regeneration can occur.
Our results favor the implication of PAs in axonal degeneration
in a dying-back motor neuronopathy and possibly in the patho-
genesis of motoneuron degeneration. Similarly, it has been
shown that PAs are implicated in axonal degeneration in amouse
model of multiple sclerosis, experimental allergic encephalomy-
elitis (Lu et al., 2002; East et al., 2005). Thus, PAs could be impli-
cated in axonal degeneration under different pathological
conditions.
It has been shown previously that uPA is activated in wobbler
mouse muscle, another mouse model of motoneuron disease
(Blondet et al., 1992), but our results are the first to implicate PAs
in axonal degeneration and motoneuron loss in a dying-back
motor neuronopathy. More importantly, they also show that in-
creased expression of an inhibitor of these enzymes affects the
outcome of the disease. It will be interesting to determine
whether the attenuation of PA activity may offer a new strategy
for delaying axonal degeneration andmotoneuron loss in neuro-
degenerative disorders.
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